XP800 in subjects with Ovarian Cancer
Phase 1
- Conditions
- Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinomaTherapeutic area: Diseases [C] - Neoplasms [C04]MedDRA version: 20.0Level: PTClassification code: 10073269Term: Ovarian endometrioid carcinoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10073268Term: Ovarian clear cell carcinoma Class: 100000004864
- Registration Number
- CTIS2023-509150-64-00
- Lead Sponsor
- uvectis Pharma Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method